Quantcast

Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.

February 13, 2009

NEW YORK, Feb. 13 /PRNewswire/ — Crystal Research Associates, LLC
announced today that it has issued an updated Executive Informational
Overview(R) (EIO(R)) on Bioniche Life Sciences Inc. (BNC: TSX). The full
68-page report can be found at www.crystalra.com.

Bioniche Life Sciences Inc. (“Bioniche” or “the Company”) is a Canadian
biopharmaceutical company that aims to improve the quality of life in both
humans and animals through innovative research, technologies, and
therapeutics. To develop the proprietary platform technologies that the
Company uses to create human and animal therapeutic agents, Bioniche is
structured in three global business units: (1) Bioniche Therapeutics (Human
Health); (2) Bioniche Animal Health; and (3) Bioniche Food Safety.

The Company’s most advanced Human Health product candidate is
Urocidin(TM), a treatment for non-muscle-invasive bladder cancer that entered
Phase III clinical development in late 2006 after the U.S. Food and Drug
Administration (FDA) granted Bioniche Fast Track status. A second Phase III
trial is likely to begin under the FDA’s Special Protocol Assessment (SPA) and
Fast Track designations after the current Phase III trial is fully enrolled
and when financing is available.

Bioniche Animal Health markets over 100 products globally, developing
products that enhance reproductive performance in animals and reduce the
animal health industry’s reliance on antibiotics. With fiscal 2008 revenues of
C$17.5 million, the line of reproductive products comprises Bioniche Animal
Health’s largest sales category. As a whole, the business unit had fiscal 2008
revenues of C$27.7 million. A lead Animal Health product is Folltropin(R)-V, a
reproductive hormone that induces superovulation in cattle and sheep.

Bioniche Food Safety develops veterinary biopharmaceuticals to improve the
safety of human food and water supplies. Its most significant initiative is
Econiche(TM), a vaccine administered to cattle that reduces the level of
Escherichia coli (E. coli) O157:H7 that cattle shed, thus minimizing the risk
of human illness from contaminated food or water. The vaccine was fully
licensed in Canada in October 2008. In addition, in mid-2008, the Company
secured C$25 million in government funding for a vaccine production facility
scale-up in Belleville, Ontario, Canada, as part of a long-term C$107 million
project to create an Animal Health and Food Safety Vaccine Manufacturing
Centre.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm that
provides institutional-quality, fee-based research to small and mid-cap
companies. Crystal Research Associates’ unique and novel product, the
Executive Informational Overview(R) (EIO(R)), is free of investment ratings,
target prices, and forward-looking financial models. The EIO(R) presents a
crystal clear, detailed report on a company (public or private) in a manner
that is easily understood by the Wall Street financial community. The EIO(R)
details a company’s product/technology/service offerings, market size(s), key
intellectual property, leadership, growth strategy, competition, risks,
financial statements, key events, and other such fundamental information.
Crystal Research Associates has offices in New York City, Delray Beach,
Montreal, and Toronto. Crystal Research Associates has been compensated by the
Company in cash of sixty-two thousand five hundred U.S. dollars and one
hundred fifty thousand Options/Warrants for its services in creating and
updating the base report, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating
results, potential applications of the Company’s technology, opportunities for
the Company, and any other statements about the future expectations, beliefs,
goals, plans, or prospects expressed constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Any statements that are not statements of historical fact (including
statements containing the words “will,” “believes,” “plans,” “anticipates,”
“expects,” “estimates,” and similar expressions) should also be considered to
be forward-looking statements. There are a number of important factors that
could cause actual results or events to differ materially from those indicated
by such forward-looking statements including, limited operating history, need
for future capital, and economic conditions generally. Additional information
on potential factors that could affect results and other risks and
uncertainties are detailed from time to time in the Company’s periodic
reports, including forms filed with SEDAR.

These statements, and other forward-looking statements, are not guarantees
of future performance and involve risks and uncertainties. Crystal Research
Associates assumes no obligation to update any of the forward-looking
statements in this release.

SOURCE Crystal Research Associates, LLC


Source: newswire



comments powered by Disqus